Amgen's experimental drug MariTide has demonstrated its effectiveness in helping trial patients sustain weight loss while significantly lowering HBA1C levels, solidifying the company's position in obesity treatment. Concurrently, the acquisition of Dark Blue is poised to financially benefit Evotec, valued at up to $840 million. Despite facing valuation pressures and institutional dominance among shareholders, Amgen maintains strong financial health, with robust revenue growth and well-supported dividends, and is preparing to launch innovative therapies like Olpasiran targeting atherosclerotic cardiovascular disease.
“Amgen says MariTide helped trial patients maintain weight loss”
“Amgen says MariTide helped trial patients maintain weight loss https://t.co/9BylCTcqsg”
“AMGEN: 24-WEEK STUDY OF MONTHLY MARITIDE IN PEOPLE WITH TYPE 2 DIABETES SHOWED ROBUST, CLINICALLY MEANINGFUL REDUCTION IN BOTH HBA1C, WEIGHT”
“Amgen’s experimental drug MariTide helped patients maintain weight loss for two years, a positive development for the company that is trying to establish itself as a competitor in obesity treatment”
“The grant comes on the heels of reports that Evotec is poised to benefit from Amgen’s Dark Blue Acquisition. As one of the early collaborators and investors in Oxford-based Dark Blue, the company is entitled to some proceeds from the transaction. The transaction carries a potential value of up to $840 million.”
“Since institutional investors own more than half the issued stock, the board will likely have to pay attention to their preferences. We note that hedge funds don't have a meaningful investment in Amgen. The company's largest shareholder is The Vanguard Group, Inc., with ownership of 10%. For context, the second largest shareholder holds about 8.5% of the shares outstanding, followed by an ownership of 8.1% by the third-largest shareholder.”
“Our most recent data indicates that insiders own less than 1% of Amgen Inc.. As it is a large company, we'd only expect insiders to own a small percentage of it.”
“Because institutional owners have a huge pool of resources and liquidity, their investing decisions tend to carry a great deal of weight, especially with individual investors.”
“Amgen reported early Phase 2 data suggesting patients kept weight off with less frequent dosing, a potential differentiator from Eli Lilly and Novo Nordisk.”
“On that day, Amgen is projected to report earnings of $4.72 per share, which would represent a year-over-year decline of 11.11%.”
“Amgen currently has a Forward P/E ratio of 14.97. For comparison, its industry has an average Forward P/E of 20.82, which means Amgen is trading at a discount to the group.”
“The market, however, still views Amgen primarily as a stable dividend play, underestimating its accelerating topline growth and robust pipeline.”